MarginsXMarginsX
Home › Markets › Health Care › ASND

Ascendis Pharma A/S Ordinary Share (ASND)

ASND trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$271.73
-1.33% on the day
Market cap
$17.9B
Large cap
Revenue · 2025
$795.9M
+98.0% on 2024
Net income · 2025
-$252.0M
-31.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/0001193125-26-046590-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerASND on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryDenmark
IPO year2015
SEC CIK0001612042
SEC industry codePharmaceutical Preparations
Incorporated inDenmark

Financials · 2025

LineValue
Revenue$795.9M
Net income-$252.0M
Operating income-$150.6M
Net margin-31.7%
Operating margin-18.9%
Revenue growth+98.0%
Cash$680.8M
Total assets$1.4B
P/E (computed)Net income was not positive
P/S (computed)22.5×

Reported in EUR; shown in US dollars.

Warning signs

Cash runway
Cash-flow positive
616.0M EUR cash at December 31, 2025
Share count, 1 year
+2.1%
2024-12-31 to 2025-12-31 · +8.4% over 3 years
Going-concern doubt
No
20-F filed February 11, 2026
Insider net buying, 12 months
-$4.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-02-11
Cash and burn616.0M EUR cash; operating cash flow 13.5M EUR a quarter.Report 2025-12-31
Shares outstanding61,977,408 (2025-12-31); 60,689,487 a year earlier; 57,152,295 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte Statsautoriseret Revisionspartnerselskab, Copenhagen, DenmarkPCAOB Form AP 2026-03-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $777K, sold $5.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
720.1M EUR-228.0M EUR53.9M EUR616.0M EUR720.3M EUR720.1M EUR20-F 2026-02-11
FY 2024
2024-12-31
363.6M EUR-378.1M EUR-306.2M EUR559.5M EUR763.6M EUR363.6M EUR20-F 2026-02-11
FY 2023
2023-12-31
266.7M EUR-481.4M EUR-467.4M EUR392.2M EUR545.5M EUR266.7M EUR20-F 2026-02-11
FY 2022
2022-12-31
51.2M EUR-583.2M EUR-495.7M EUR444.8M EUR399.2M EUR51.2M EUR20-F 2025-02-12
FY 2021
2021-12-31
7.8M EUR-383.6M EUR-417.6M EUR446.3M EUR105.0M EUR7.8M EUR20-F 2024-02-07
FY 2020
2020-12-31
7.0M EUR-419.0M EUR-271.5M EUR584.5M EURNo debt tags7.0M EUR20-F 2023-02-16
FY 2019
2019-12-31
13.4M EUR-218.0M EUR-175.9M EUR598.1M EURNo debt tags13.4M EUR20-F 2022-03-02
FY 2018
2018-12-31
10.6M EUR-130.1M EUR-138.8M EUR277.9M EURNo debt tags10.6M EUR20-F 2021-03-10

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52024-09-20
Latest annual report20-F2026-02-11
Latest quarterly / interim6-K2026-11-12

Source: SEC EDGAR submissions feed, 801 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+7.2%
1 month+23.4%
3 months+11.8%
Year to date+29.1%
1 year+33.4%
From 52-week high-0.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
JAZZJazz Pharmaceuticals plc Common Stock (Ireland)$239.77-0.74%$15.4B
BBIOBridgeBio Pharma Inc.$77.36-1.20%$15.1B
ALNYAlnylam Pharmaceuticals Inc.$159.73-3.22%$21.4B
VTRSViatris Inc.$20.74-0.38%$23.8B
ELANElanco Animal Health Incorporated$26.41-1.38%$13.2B
UTHRUnited Therapeutics Corporation$587.88-0.56%$25.0B
RDYDr. Reddy's Laboratories Ltd$14.70-0.27%$12.3B
INSMInsmed Incorporated$122.88+1.42%$27.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier